Skip to main content

Advertisement

Table 2 Changes from baseline to week 8 of anthropometric and metabolic parameters in cilostazol and placebo group (n=37)

From: Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial

  Placebo Cilostazol
  Baseline Follow-up P-value Baseline Follow-up P-value
BMI (kg/m2) 26.2 ± 2.9 26.2 ± 2.9 0.29 26.2 ± 2.9 26.0 ± 2.9 0.12
Waist circumference (cm) 92.5 ± 8.0 92.1 ± 7.6 0.36 92.6 ± 8.0 91.4 ± 7.4 0.007
Systolic blood pressure (mmHg) 131.0 ± 10.8 131.1 ± 12.0 0.93 130.6 ± 11.2 129.6 ± 13.0 0.59
Diastolic blood pressure (mmHg) 79.6 ± 11.2 81.3 ± 10.3 0.35 79.4 ± 9.8 77.4 ± 9.3 0.20
Fasting glucose (mg/dL) 129.2 ± 22.2 129.6 ± 32.0 0.94 137.5 ± 41.2 140.2 ± 31.7 0.66
HbA1c (%)* 7.2 ± 1.2 7.1 ± 1.2 0.19 7.3 ± 1.2 7.2 ± 1.2 0.42
Fasting insulin (μIU/mL)* 11.0 ± 1.6 11.0 ± 1.6 0.99 11.1 ± 1.5 10.3 ± 1.5 0.21
HOMA-IR* 3.5 ± 1.6 3.6 ± 1.7 0.50 3.6 ± 1.6 3.5 ± 1.6 0.73
QUICKI 0.32 ± 0.02 0.32 ± 0.02 0.59 0.32 ± 0.02 0.32 ± 0.02 0.74
Total cholesterol (mg/dL) 156.7 ± 24.2 154.1 ± 23.6 0.49 157.9 ± 21.0 154.9 ± 23.0 0.39
Triglyceride (mg/dL)* 143.9 ± 1.7 140.7 ± 1.6 0.77 134.6 ± 1.6 121.9 ± 1.5 0.19
HDL-C (mg/dL) 43.0 ± 9.3 44.7 ± 13.1 0.37 47.1 ± 11.0 48.1 ± 10.9 0.41
LDL-C (mg/dL) 94.1 ± 21.6 90.3 ± 19.9 0.28 93.9 ± 19.9 88.9 ± 20.0 0.10
hsCRP (mg/L)* 1.09 ± 2.78 0.93 ± 3.28 0.39 0.90± 2.79 1.15 ± 2.24 0.09
Mean baPWV (cm/sec) 1597.9 ± 239.6 1606.7 ± 259.6 0.77 1621.8 ± 229.8 1592.0 ± 249.3 0.35
Adiponectin (ng/mL)* 8.44 ± 1.82 8.53 ± 1.95 0.72 9.17 ± 1.88 9.92 ± 1.93 0.07
IL-6 (pg/mL)* 4.13 ± 3.14 3.21 ± 3.34 0.02 4.33 ± 3.28 3.41 ± 2.48 0.74
TNF-α (ng/dL)* 6.66 ± 1.32 6.12 ± 1.36 0.07 6.42 ± 1.32 6.36 ± 1.37 0.87
MCP-1 (ng/dL)* 546.6 ± 1.43 577.5 ± 1.38 0.32 588.1 ± 1.57 570.4 ± 1.43 0.67
sVCAM-1 (ng/dL) 1227.6 ± 274.0 1225.1 ± 281.4 0.94 1288.7 ± 285.6 1168.2 ± 252.3 0.0003
sICAM-1 (ng/dL)* 158.4 ± 1.38 156.3 ± 1.39 0.70 155.2 ± 1.38 144.0 ± 1.35 0.10
  1. HOMA-IR homeostasis model assessment of insulin resistance, QUICKI quantitative insulin sensitivity check index, hsCRP high sensitivity C-reactive protein, baPWV brachial-ankle pulse wave velocity, IL-6 interleukin-6, TNF-α tumor necrosis factor-alpha, MCP-1 monocyte chemotactic protein-1, sVCAM-1 soluble vascular cellular adhesion molecule-1, sICAM-1 soluble intercellular adhesion molecule-1.
  2. Data are presented as the mean ± SD.
  3. *Geometric mean ± SD, statistical significance was estimated after logarithmic transformation.
  4. P-value were obtained using paired t-test based on change (follow-up–baseline) in each group.